NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT06663137,Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC,https://clinicaltrials.gov/study/NCT06663137,HGNMIBC,RECRUITING,High-grade NMIBC is more aggressive cancer that has a higher risk of progression and recurrence compared to low-grade NMIBC. NDV01 is a novel controlled release intravesical formulation designed for the treatment of non-muscle invasive bladder cancer (NMIBC).,NO,Non Muscle Invasive Bladder Cancer,DRUG: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel,"Number of Patients with Complete Response (CR) in High-Grade NMIBC, Complete response is defined by at least one of the following criteria:

Negative cystoscopy and negative or atypical urine cytology; and/or Positive cystoscopy with biopsy-confirmed benign or low-grade NMIBC, along with negative urine cytology., 48 weeks|Frequency and severity of Adverse Events (AEs), including Serious Adverse Events (SAEs) and Treatment-emergent AEs (TEAEs) occurring at any time during the study Serious Adverse Events (SAEs) Treatment-Emergent Adverse Events (TEAEs), Any new Change from Baseline to End of Study (EOS) in investigators assessment, 48 weeks","Durability of Complete Response (CR) in High-Grade NMIBC, Evaluate how long patients maintain CR over time., 48 weeks|Number of Patients with CR Among Those with Carcinoma In Situ (CIS), Includes those with or without co-existing high-grade Ta or T1 papillary disease., 48 weeks|Incidence of Event-Free Survival (EFS) at 12 Months, Event-free survival is defined as survival without recurrence of high-grade disease., 48 weeks|Durability of event-free survival in patients with high-grade Ta or T1 papillary disease (without concomitant CIS), who have no recurrence of high-grade Ta or T1 papillary disease, Tumor recurrence, 48 weeks","Pharmacokinetic parameters of NDV01 KIT will be evaluated, PK measurement expressed as maximum plasma concentration for NDV01 and PK measurement expressed as half-life and area under curve for NDV01 Pharmacokinetic (PK)., 20 weeks",Trigone Pharma Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE2,70,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,TRGC-011,2024-08-01,2025-08,2026-08,2024-10-29,,2024-10-29,"Avi Gordon, Raanana, 4363007, Israel",
